The University of Antwerp has identified new quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one HER4 (ERBB4) inhibitors reported to be useful for the treatment of heart failure, cancer, fibrosis, and metabolic and inflammatory disorders.